The general Concepts of Pharmacokinetics

Similar documents
Pharmacodynamic indices in targeting therapy of critical infections

PHA Spring First Exam. 8 Aminoglycosides (5 points)

Towards clinical Applications of PK-PD in specific situations

Basic Concepts of TDM

Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets of β-lactams in critically ill patients at first dose: Can we do it with standard dosing?

PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS

ICU Volume 11 - Issue 3 - Autumn Series

ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO

General Principles of Pharmacology and Toxicology

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Lessons from recent studies. João Gonçalves Pereira UCIP DALI

prophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures

Name: UFID: PHA Exam 2. Spring 2013

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

PHA Final Exam Fall 2006

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHARMONITOR II. Optimisation of aminoglycosides dosage regimen with pharmacokinetics modeling. Pierre Wallemacq

TDM. Measurement techniques used to determine cyclosporine level include:

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

PK/PD degli antibiotici utilizzati nella sepsi

Determination of bioavailability

Integration of Target Site Pharmacokinetics and in-vitro Pharmacodynamics in the Assessment of Existing and New Anti-Infective Agents

Renal Impairment From Dettli to Guideline: What can we learn?

BASIC PHARMACOKINETICS

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN

Continuous Renal Replacement Therapy. Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD

Continuous Renal Replacement Therapy

Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment

Multiple IV Bolus Dose Administration

WHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook

PHA 5128 Spring 2009 First Exam (Version B)

Optimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Section 5.2: Pharmacokinetic properties

Click to edit Master title style

Pharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen

Pharmacokinetic parameters: Halflife

Doripenem: pharmacokinetics and pharmacodynamics. Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD

Basic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics

PHA 5128 Spring 2000 Final Exam

BIOPHARMACEUTICS and CLINICAL PHARMACY

GLYCOPEPTIDES : how can a structural modification bring to a new life an old family of antibiotics?

The importance of clearance

Pharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core

Drug Management in CRRT

Pharmacodynamics: the methods

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Pharmacokinetics One- compartment Open Model Lec:2

- SLED Sustained Low-Efficiency Dialysis

Valproate overdose: what is the role of carnitine?

Is the package insert correct? PK considerations

PHA First Exam. Fall 2004

PHA Final Exam Fall 2001

JAC Computer-aided prediction of macrolide antibiotic concentrations in human circulating polymorphonuclear leucocytes

Therapeutic drug monitoring of β-lactams

Treatment of Tuberculosis Therapeutic Drug Monitoring

Pharmacodynamics & Pharmacokinetics 1

Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations

Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017

Biomath M263 Clinical Pharmacology

PHA5128 Dose Optimization II Case Study I Spring 2013

Activity of antibiotics against intracellular S. aureus

Should we be performing TDM in seriously ill patients with Gram negative infections?

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

PHA First Exam Fall 2003

TDM of Aminoglycoside Antibiotics

Counties in the top and bottom two quintiles of both diabetes and obesity, Age-adjusted percentage of adults aged 20 years who are obese, 2007

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

PHARMACOKINETICS SMALL GROUP I:

C OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:

HIV/Sexual Health Clinical Education Session

Pharmacokinetics Overview

Pharmacokinetic Calculations

Basic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Outline 8/2/2013. PK/PD PK/PD first-line drug กก PK/PD กก

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

Vancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy

Clinical Trials A Practical Guide to Design, Analysis, and Reporting

Comparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects

Pharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis

Overview. Therapeutic Window. Does drug concentration matter? Treatment of Tuberculosis Therapeutic Drug Monitoring

AUGMENTED RENAL CLEARANCE and its clinical implications. Professor Jeffrey Lipman

Noncompartmental Analysis (NCA) in PK, PK-based Design

Thus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.

PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

PHAR 7633 Chapter 20 Non Compartmental Analysis

Dr. M.Mothilal Assistant professor

CRRT and Drug dosing. Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017

Principal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA

Title. Author(s)Hayakawa, Mineji; Fujita, Itaru; Iseki, Ken; Gando, CitationASAIO Journal, 55(3): Issue Date Doc URL. Rights.

pharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.

We will begin momentarily at 2pm ET. Slides available now! Recordings will be available to ACS members after one week.

Transcription:

The general Concepts of Pharmacokinetics What is this jargon? Is it useful? C max, clearance, Vd, half-life, AUC, bioavailability, protein binding F. Van Bambeke, E. Ampe, P.M. Tulkens (Université catholique de Louvain, Brussels, Belgium) With some slides from H. Derendorf (University of Florida) 1

Pharmacokinetics (PK) is speed! 2

What is pharmacokinetics? " what the body does to the drug " the fate of the drug in terms of Absorption Distribution Metabolism Excretion the time course of drug and metabolite concentrations in the body 3

What is pharmacokinetics? " what the body does to the drug " the fate of the drug in terms of Absorption Distribution Metabolism Excretion Pharmacokinetics 0.4= conc. vs time Conc. 0.0 0 25 Time the time course of drug and metabolite concentrations in the body 4

What is PK for? PK is the way to see if the drug can be made useful does it reach the target in sufficient amounts? for long enough? Pharmacokinetics 0.4= conc. vs time does it each non-desired targets? Conc. 0.0 0 25 Time 5

The C max is the highest concentration in plasma after administration... concentration dose = 1 C max time 6

C max... is proportional to the dose... concentration dose = 1 dose = 2 C max C max time 7

What is the significance of the C max? A drug with a (too) low C max may be ineffective if its activity is concentration-dependent A drug with a (too) high C max may become toxic if toxicity is related to C max (this NOT always the case...!) you have to adjust the dose to get the appropriate C max! 8

Clearance (Cl) in C i C o Q Eliminating Organ Quantity eliminated per unit of time out C o < C i the rate at which the drug will be excreted is proportional to the blood flow in the eliminating organ (Q) the extraction the organ is capable of (E) the clearance is thus Q x E (= L/h or ml/min) 9

Clearance Clearance can be calculated from Excretion rate / Concentration e.g. (mg/h) / (mg/l) = L/h Dose / Area under the curve (AUC) e.g. mg / (mg h/l) = L/h 10

Clearance Total body clearance is the sum of the individual organ clearances CL = CL renal + CL hepatic + CL other 11

What is the significance of the clearance? A drug with a fast clearance will not stay around for long and may require readminstration... But a drug may show a slow clearance because it is bound to proteins and therefore largely unavailable (see later ) If clearance falls during treatment (or is abnormally low at the beginning of treatment), patient will be overdosed!! 12

Volume of distribution (V d ) Quantifies how the drug has access to the various compartments of the body relates drug concentration (C) in the blood to the amount of drug that has been introduced in the body (= Dose) V d = Dose / Concentration in blood 13

What is V d? Think about the body as a large "bag" with compartments in which you drop a drug... D plasma tissue 14

What is V d? If drug diffuses throughout the body... Vd = 1 L/kg D D D serum concentration = tissue concentration 15

What is V d? If the drug reaches only the plasma and the extracelular fluids... Vd < 1 L/kg C max D D high serum concentration no or little tissue concentration 16

What is V d? If drug accumulates in tissues... Vd > 1 L/kg C max D D low serum concentration high tissue concentration 17

Typical volumes of distribution of antibiotics L/kg dicloxacillin 0.1 (serum only) gentamicin 0.25 (serum plus extracell. fluids) ciprofloxacin 1.8 (fluids plus moderate accumulation in tissues) azithromycin 31 (marked accumulation in tissues) 18

What is the clinical significance of the Vd? A drug with a small V d will have high initial blood levels but will not reach tissues... A large V d will cause low initial blood levels if patient-related, you will need to give more of the drug (e.g., burn patients) if drug-related, it may become ineffective in blood-related (invasive) infections 19

Half-life (t 1/2 ) Half-life is the time it takes for the concentration to fall to half of its previous value This is a parameter which is easy to measure, (just take a few blood samples ) BUT... it is secondary pharmacokinetic parameter because it depends on both the clearance AND the volume of distribution 20

Why is half half-life a secondary parameter? You start from here, but this is C max, i.e. Dose / Vd And you follow a slope which is dictated by the drug elimination rate, i.e the total body clearance 21

Why is half half-life a secondary parameter? t 1/ 2 = 0. 693 CL Vd 22

What is useful in half-life for the clinician? Direct information as how serum concentrations will fall over time and reach a pre-set threshold... if you know the C max (i.e. your starting point) Direct, practical comparisons between drugs if sharing the same V d... You can compare β-lactams between themselves for half-life,... BUT you CANNOT compare β-lactams (low V d ) and azithromycin (high V d ), e.g. 23

Area under the Curve (AUC) Peak area under the curve trough AUC = dose / clearance 24

combines Area under the Curve (AUC) one parameter directly linked to the medical decision: the dose of the drug! one parameter linked to the drug AND the patient: the clearance... its value is independent of the scheme of administration... useful to assess the total drug exposure 25

Determination of the AUC AUC = Ci + Ci [ ( ) ( ti ti 1)] 2 n 1 Σ i = 1 26

Cp ave(ss) AUC 1 AUC ss 27

24h-AUC / MIC of fluoroquinolones (p.o.) Drug Dosage 24h-AUC (mg/24h) (mg/l x h) norfloxacin 800 14 *, # ciprofloxacin 500 12 * ofloxacin 400 31 to 66 *, + levofloxacin 500 47 * moxifloxacin 400 48 * poor if MIC is Much better!! * US prescrib. inf. (adult of 60 kg) of NOROXIN, CIPRO, FLOXIN, LEVAQUIN, and AVELOX # litterature data + first dose to equilibrium 28

Bioavailability quantifies ABSORPTION from the site of administration to the blood is measured by comparing oral (or another mode of administration) to intravenous administration A poor bioavailability reduces both C max and AUC... and thereby decreases the potential for efficacy!!! 29

A low bioavailability (F) reduces both C max and AUC F = 1 C max concentration C max F = 0.5 time 30

Fluoroquinolones : influence of cations on bioavailability A. Cipro 750 mg B. + 850 mg CaCO 3 C. + 600 mg Al(OH) 3 Frost et al AAC (1992) 36:830-2 31

Fluoroquinolones : bioavailability (p.o.) and C max Drug Dosage Bioav. C max (mg/24h) (%) (mg/l) norfloxacin 800 ~ 35 2.4 * ciprofloxacin 500 ~ 70 2.4 * ofloxacin 400 ~ 95 3-4.5 *, + levofloxacin 500 ~ 99 5-6 *, + moxifloxacin 400 ~ 90 4.5 * * US prescrib. inf. (adult of 60 kg) of NOROXIN, CIPRO, FLOXIN, LEVAQUIN, and AVELOX + first dose to equilibrium 32

Protein binding: it is (almost always) the free drug that acts... 33

Protein binding: it is (almost always) the free drug that acts... vascular space extravascular space plasma protein binding binding to extracellular biological material blood cell binding, diffusion into blood cells, binding to intracellular biological material tissue cell binding, diffusion into tissue cells, binding to intracellular biological material 34

Microdialysis Dialysate Perfusate Interstitium Capillary Cell 35

Microdialysis 36

Protein binding impairs and slows down drug distribution... TOTAL drug concentration of ertapenem (a high protein bound β-lactam) in plasma and blister fluid after 3 days of treatment concentration (mg/l) 150 125 100 75 50 25 plasma blister 0 0 4 8 12 16 20 24 time (h) 7 37

But protein binding prolongs half-lilfe... Ertapenem 1 g Ceftriaxone 1 g 100.0 100.0 concentration (mg/l) 10.0 1.0 0.1 0.01 0 4 8 12 16 20 24 total free 10.0 1.0 0.1 0.01 0 4 8 12 16 20 24 time (h) total free ceftriaxone data: Paradis et al, AAC 1992, 36: 2085-2092 Perry & Schentag, Clin Pharmacokinet. 2001, 40: 685-694 38

Two-compartment model D Xc k 10 E k 12 k 21 Xp Dose Xc Drug in the central compartment Xp Drug in the peripheral compartment E Drug eliminated 39

C (ng/ml) 10 3 10 2 10 1 10 0 10-1 Two-compartment model 0 1 2 3 4 5 6 7 8 Time (hours) 40

A typical example for a β-lactam temocillin Laterre et al, JAC 2015, 70:891 898 41

Three-compartment model d Xp D k 31 k 13 Xc k 10 E k 12 k 21 Xp s E D Dose Drug eliminated Xc Xps Xpd Drug in the central compartment Drug in the shallow peripheral compartment Drug in the deep peripheral compartment 42

Three-compartment model α-phase: β-phase: γ-phase: distribution phase rapid elimination phase slow elimination phase α t β t γ t C = a e + b e + c e 43

Three-compartment model The example of oritavancin single dose treatment! 1 week 1 month UCL PK/PD Course June 2017 44

PHARMACOKINETICS what the body does to the drug PHARMACODYNAMICS what the drug does to the body 45

Pharmacokinetics 0.4 conc. vs time Pharmacodynamics 1 conc. vs effect Conc. 0.0 0 25 Time 0 10 Conc (log) -4 10-3 1 PK/PD effect vs time Effect Effect 0 0 25 Time 46